Am Heart J

1. WANG X, Guo R, Guo Y, Guo Q, et al
   Rationale and design of the RESTORE trial: A multicenter, randomized, double-blinded, parallel-group, placebo-controlled trial to evaluate the effect of Shenfu injection on myocardial injury in STEMI patients after primary PCI.
   Am Heart J. 2023;260:9-17.
   

   >> Share

   
   
2. ARNOLD SV, Gosch K, Kosiborod M, Wong ND, et al
   Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes. Insights from The Diabetes Collaborative Registry.
   Am Heart J. 2023 May 8:S0002-8703(23)00112-6. doi: 10.1016/j.ahj.2023.
   

   >> Share

   
   

   
   Am J Cardiol

3. SUZUKI K, Kinoshita D, Sugiyama T, Yuki H, et al
   Coronary Computed Tomography Angiography Findings of Plaque Erosion.
   Am J Cardiol. 2023;196:52-58.
   

   >> Share

   
   
4. CHEN K, Davidson LJ, Sweis RN, Flaherty JD, et al
   Heart Attack After TAVR: Are We Taking It Seriously Enough?
   Am J Cardiol. 2023;196:102-103.
   

   >> Share

   
   
5. REMPAKOS A, Kostantinis S, Simsek B, Karacsonyi J, et al
   Procedural Time and Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention.
   Am J Cardiol. 2023;197:55-64.
   

   >> Share

   
   

   
   Ann Intern Med

6. RICHARDSON TL JR, Halvorson AE, Hackstadt AJ, Hung AM, et al
   Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
   Ann Intern Med. 2023 May 9. doi: 10.7326/M22-2751.
   

   >> Share

   
   

   
   Catheter Cardiovasc Interv

7. CALI F, Pagnesi M, Pezzola E, Montisci A, et al
   Transcatheter edge-to-edge mitral valve repair for post-myocardial infarction papillary muscle rupture and acute heart failure: A systematic review.
   Catheter Cardiovasc Interv. 2023 May 10. doi: 10.1002/ccd.30682.
   

   >> Share

   
   
8. RIGATTIERI S, Casenghi M
   Lowering air kerma to improve the CTO operator's karma.
   Catheter Cardiovasc Interv. 2023;101:1172-1173.
   

   >> Share

   
   
9. FELDMAN D, Cao D, Sartori S, Zhang Z, et al
   Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
   Catheter Cardiovasc Interv. 2023;101:1134-1143.
   

   >> Share

   
   
10. A PRADO GF, Blanco PJ, Bulant CA, Ares GD, et al
    Quantitative coronary three-dimensional geometry and its association with atherosclerotic disease burden and composition.
    Catheter Cardiovasc Interv. 2023;101:1036-1044.
    

    >> Share

    
    
11. HANNAN EL, Zhong Y, Cozzens K, Osinaga A, et al
    Impact of COVID-19 on percutaneous coronary intervention utilization and mortality in New York.
    Catheter Cardiovasc Interv. 2023 Apr 1. doi: 10.1002/ccd.30648.
    

    >> Share

    
    
12. MORONI A, Marin F, Venturi G, Scarsini R, et al
    Management of failed stenting of the unprotected left main coronary artery.
    Catheter Cardiovasc Interv. 2023;101:1001-1013.
    

    >> Share

    
    
13. MASSUSSI M, Adamo M, Rosati F, Chizzola G, et al
    Coronary artery disease and TAVI: Current evidence on a recurrent issue.
    Catheter Cardiovasc Interv. 2023;101:1154-1160.
    

    >> Share

    
    
14. BUYUKGOZ C, Sandhu H, Shah S, Rower K, et al
    Strategies and techniques for percutaneous Veno-Arterial ECMO cannulation and decannulation in children.
    Catheter Cardiovasc Interv. 2023;101:1088-1097.
    

    >> Share

    
    
15. MORETTI F, Rondi M, Ottani F
    Zero-contrast IVUS-guided complex PCI in a patient with NSTE-ACS and severe renal impairment.
    Catheter Cardiovasc Interv. 2023;101:1074-1080.
    

    >> Share

    
    
16. TORABI AJ, Von der Lohe E, Kovacs RJ, Frick KA, et al
    Measures of social deprivation and outcomes after percutaneous coronary intervention.
    Catheter Cardiovasc Interv. 2023 Mar 30. doi: 10.1002/ccd.30642.
    

    >> Share

    
    
17. SIMSEK B, Khatri J, Young L, Kostantinis S, et al
    Same day discharge versus overnight observation following chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS-CTO registry.
    Catheter Cardiovasc Interv. 2023 Mar 24. doi: 10.1002/ccd.30644.
    

    >> Share

    
    
18. YUASA S, Lauri FM, Mejia-Renteria H, Liontou C, et al
    Angiography-derived functional assessment of left main coronary stenoses.
    Catheter Cardiovasc Interv. 2023 Mar 19. doi: 10.1002/ccd.30633.
    

    >> Share

    
    
19. SETO AH
    Cut, score, press, shock, or ablate?
    Catheter Cardiovasc Interv. 2023;101:975-977.
    

    >> Share

    
    
20. MUSUMECI G, Quadri G
    Bioresorbable scaffolds: Still alive in low-risk coronary artery disease.
    Catheter Cardiovasc Interv. 2023;101:973-974.
    

    >> Share

    
    
21. EL HAJJ M, Krajcer Z
    Bioresorbable stents: We have more work to do.
    Catheter Cardiovasc Interv. 2023;101:978-979.
    

    >> Share

    
    
22. WANG X, Li Y, Fu G, Xu B, et al
    Three-year clinical outcomes of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: A prospective patient-level pooled analysis of NeoVas trials.
    Catheter Cardiovasc Interv. 2023;101:967-972.
    

    >> Share

    
    

    
    Circ Cardiovasc Imaging

23. MADIAS JE
    Letter by Madias Regarding Article, "Recurrent Takotsubo Cardiomyopathy and Myocardial Infarction due to Aberrant Right Coronary Artery in a Patient With Nonobstructive Coronary Arteries".
    Circ Cardiovasc Imaging. 2023 May 8:e015435. doi: 10.1161/CIRCIMAGING.123.015435
    

    >> Share

    
    
24. ACKERSCHOTT A, Luetkens J, Nickenig G, Zachoval C, et al
    Response to Letter Regarding Article, "Recurrent Takotsubo Cardiomyopathy and Myocardial Infarction Due to Aberrant Right Coronary Artery in a Patient With Nonobstructive Coronary Arteries".
    Circ Cardiovasc Imaging. 2023 May 8:e015459. doi: 10.1161/CIRCIMAGING.123.015459
    

    >> Share

    
    
25. GILARD M, Wijns W
    High-Intensity Lipid-Lowering Therapies: An Opportunity for Improving Cardiovascular Outcomes in Postmenopausal Women?
    Circ Cardiovasc Imaging. 2023 May 10:e015544.
    

    >> Share

    
    

    
    Circ Res

26. WANG RS, Loscalzo J
    Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations.
    Circ Res. 2023;132:1374-1386.
    

    >> Share

    
    
27. BOULOS PK, Freeman SV, Henry TD, Mahmud E, et al
    Interaction of COVID-19 With Common Cardiovascular Disorders.
    Circ Res. 2023;132:1259-1271.
    

    >> Share

    
    
28. SINGH TK, Zidar DA, McCrae K, Highland KB, et al
    A Post-Pandemic Enigma: The Cardiovascular Impact of Post-Acute Sequelae of SARS-CoV-2.
    Circ Res. 2023;132:1358-1373.
    

    >> Share

    
    
29. KOUPENOVA M, Chung MK, Bristow MR
    COVID-19 and the Cardiovascular System: Requiem for a Medical Minotaur.
    Circ Res. 2023;132:1255-1258.
    

    >> Share

    
    

    
    Circulation

30. KWAN TW, Wong SS, Hong Y, Kanaya AM, et al
    Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association.
    Circulation. 2023 May 8. doi: 10.1161/CIR.0000000000001145.
    

    >> Share

    
    
31. SATTAR N, McMurray J, Boren J, Rawshani A, et al
    Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
    

    >> Share

    
    

    
    Eur Heart J

32. SHEMESH E, Chevli PA, Islam T, German CA, et al
    Circulating ketone bodies and cardiovascular outcomes: the MESA study.
    Eur Heart J. 2023 Mar 6:ehad087. doi: 10.1093.
    

    >> Share

    
    
33. JIANG Y, Huang J, Li G, Wang W, et al
    Ozone pollution and hospital admissions for cardiovascular events.
    Eur Heart J. 2023 Mar 10:ehad091. doi: 10.1093.
    

    >> Share

    
    
34. VERGALLO R, Patrono C
    'Atom Heart Mothers': the risk of ischaemic heart disease in women with adverse pregnancy outcomes.
    Eur Heart J. 2023;44:1592-1593.
    

    >> Share

    
    
35. NURMOHAMED NS, Kraaijenhof JM, Mayr M, Nicholls SJ, et al
    Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction.
    Eur Heart J. 2023 Mar 29:ehad161. doi: 10.1093.
    

    >> Share

    
    
36. HAN Y
    Chinese expert consensus on clinical application of percutaneous mechanical circulatory support devices in interventional therapy for patients with complex cardiovascular disease.
    Eur Heart J. 2023;44:1586-1588.
    

    >> Share

    
    

    
    Hypertension

37. AL KHALAF S, Chappell LC, Khashan AS, McCarthy FP, et al
    Association Between Chronic Hypertension and the Risk of 12 Cardiovascular Diseases Among Parous Women: The Role of Adverse Pregnancy Outcomes.
    Hypertension. 2023 May 12. doi: 10.1161/HYPERTENSIONAHA.122.20628.
    

    >> Share

    
    
38. YU J, Song Q, Bai J, Wu S, et al
    Visit-to-Visit Blood Pressure Variability and Cardiovascular Outcomes in Patients Receiving Intensive Versus Standard Blood Pressure Control: Insights From the STEP Trial.
    Hypertension. 2023 May 12. doi: 10.1161/HYPERTENSIONAHA.122.20376.
    

    >> Share

    
    

    
    Int J Cardiol

39. ZUIN M, di Fusco SA, De Caterina R, Roncon L, et al
    Declining trends of premature mortality from ischemic heart disease and regional differences in Italy from 2011 to 2017.
    Int J Cardiol. 2023 May 8:S0167-5273(23)00649.
    

    >> Share

    
    
40. XIN A, Li K, Qian G, Chen Y, et al
    Reply to Machine learning-based prediction of infarct size in patients with ST-segment elevation myocardial infarction: Misinterpretation.
    Int J Cardiol. 2023 May 5:S0167-5273(23)00653.
    

    >> Share

    
    
41. LEE WJ, Cheng H, Whitney BM, Nance RM, et al
    Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV.
    Int J Cardiol. 2023 May 4:S0167-5273(23)00648.
    

    >> Share

    
    

    
    J Am Coll Cardiol

42. STONE GW, Gaudino M
    Reconsidering the Direction of Coronary Revascularization Trials.
    J Am Coll Cardiol. 2023;81:1974-1978.
    

    >> Share

    
    
43. STOREY RF, Parker WAE
    Thrombotic Coronary Occlusion and Reperfusion: Unraveling the Determinants.
    J Am Coll Cardiol. 2023;81:1933-1936.
    

    >> Share

    
    
44. KANJI R, Gue YX, Memtsas V, Spencer NH, et al
    Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction.
    J Am Coll Cardiol. 2023;81:1918-1932.
    

    >> Share

    
    

    
    J Cardiovasc Pharmacol

45. HASSAN AE, Hadhoud S, Elmahdi E, Elkattawy HA, et al
    Potential Cardioprotective Role of Menaquinone-4 Against Cardiac Ischemia-reperfusion Injury.
    J Cardiovasc Pharmacol. 2023;81:381-388.
    

    >> Share

    
    
46. FU C, Yu S, Liu Z, Wang J, et al
    PFKFB2 inhibits ferroptosis in myocardial ischemia/reperfusion injury through AMPK activation.
    J Cardiovasc Pharmacol. 2023 May 5. doi: 10.1097/FJC.0000000000001437.
    

    >> Share

    
    

    
    J Electrocardiol

47. DOYLE M, Dikdan S, Farzad D, Marhefka GD, et al
    Three, dynamic variants of ST segment elevations in a patient with osteosarcoma and cardiac metastasis.
    J Electrocardiol. 2023;78:29-33.
    

    >> Share

    
    

    
    J Thorac Cardiovasc Surg

48. TIAN M, Xu B, Chen L, Wu F, et al
    Outcomes of Quantitative Flow Ratio Based Functional Incomplete Revascularization after Coronary Artery Bypass Grafting Surgery.
    J Thorac Cardiovasc Surg. 2023 Apr 19:S0022-5223(23)00326.
    

    >> Share

    
    

    
    Mol Cell Biochem

49. SHARMA S, Sharma D, Dhobi M, Wang D, et al
    An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-alpha.
    Mol Cell Biochem. 2023 May 12. doi: 10.1007/s11010-023-04755.
    

    >> Share

    
    
50. SALAMA ABM, Abouleisa RRE, Ou Q, Tang XL, et al
    Transient gene therapy using cell cycle factors reverses renin-angiotensin-aldosterone system activation in heart failure rat model.
    Mol Cell Biochem. 2023;478:1245-1250.
    

    >> Share

    
    

    
    PLoS One

51. RYU JC, Bae JH, Ha SH, Kwon B, et al
    Association between lipid profile changes and risk of in-stent restenosis in ischemic stroke patients with intracranial stenosis: A retrospective cohort study.
    PLoS One. 2023;18:e0284749.
    

    >> Share

    
    
52. CHEN H, Li B, Xiao Y, Wang H, et al
    Diagnostic efficacy of the optical flow ratio in patients with coronary heart disease: A meta-analysis.
    PLoS One. 2023;18:e0285508.
    

    >> Share

    
    
53. SAKITA FM, Prattipati S, Chick J, Samu LP, et al
    Six-month blood pressure and glucose control among HIV-infected adults with elevated blood pressure and hyperglycemia in northern Tanzania: A prospective observational study.
    PLoS One. 2023;18:e0285472.
    

    >> Share

    
    

    
    Prog Cardiovasc Dis

54. NEELAND IJ
    Adipo-cardiology: The next frontier in cardiovascular disease.
    Prog Cardiovasc Dis. 2023 May 6:S0033-0620(23)00049.
    

    >> Share

    
    

    
    Thromb Haemost

55. GIANNIS D, Goldin M, Rahman H, Sison CP, et al
    Risk factors for post-discharge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities.
    Thromb Haemost. 2023 May 5. doi: 10.1055/a-2087-3003.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share